Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7176914 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7175511 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7180301 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7171378 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7172278 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7177551 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL7176860 | 0.98 | HSD17B10 (0.57) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| SCHEMBL2839207 | 0.86 | HSD17B10 (0.59) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| SCHEMBL17621 | 0.82 | HSD17B10 (0.62) | HSD17B10BRD4LIMK2ALDH1A1MEN1 | |
| Fluoride SCHEMBL10339918 | 0.81 | HSD17B10 (0.60) | HSD17B10BRD4LIMK2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | claimed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | claimed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | claimed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | claimed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | claimed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | claimed |
| EP-2271338-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2011-01-12 | — | — | EP | claimed |
| EP-2249832-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2010-11-17 | — | — | EP | claimed |
| WO-2009123569-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-08 | — | — | WO | claimed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | claimed |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | disclosed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | disclosed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | disclosed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | disclosed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | disclosed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | disclosed |
| EP-2271338-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2011-01-12 | — | — | EP | disclosed |
| EP-2249832-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009123569-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | SMN1; SMN2, INA, NLN | HSD17B10 3606/4885BRD4 1108/4885LIMK2 1432/4885 |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | HSD17B10 3888/4885BRD4 150/4885LIMK2 2153/4885 |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | HSD17B10 3888/4885BRD4 150/4885LIMK2 2153/4885 |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | HSD17B10 3888/4885BRD4 150/4885LIMK2 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.